{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:44Z","timestamp":1792813244542,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.rbmo.2021.01.023","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T20:55:50Z","timestamp":1612904150000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Osamu","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan-Carles","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2021.01.023_bib0001","first-page":"6","article-title":"Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management","volume":"10","author":"Alper","year":"2009","journal-title":"J. Exp. Clin. Assist. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0002","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rbmo.2017.01.012","article-title":"A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF\/ICSI cycles","volume":"34","author":"Allegra","year":"2017","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2015.07.1151","article-title":"Gonadotropin dose is negatively correlated with live birth rate: analysis of over 650,000 ART cycles","volume":"104","author":"Baker","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fendo.2020.00067","article-title":"The future of cryopreservation in assisted reproductive technologies","volume":"11","author":"Bosch","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0005","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/humupd\/dmu020","article-title":"Anti-M\u00fcllerian hormone: ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rbmo.2015.05.015","article-title":"Investigating the effect of ethnicity on IVF outcome","volume":"31","author":"Dhillon","year":"2015","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0007","first-page":"1","article-title":"ART in Europe, 2016: results generated from European registries by ESHRE","author":"Wyns","year":"2020","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmm034","article-title":"Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation","volume":"14","author":"Fauser","year":"2008","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0009","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.rbmo.2012.02.027","article-title":"Can anti-M\u00fcllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?","volume":"26","author":"Fleming","year":"2013","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0010","unstructured":"Follistim 300 IU, 600 IU and 900 IU. Prescribing information. 2015; Version 8 (product discontinued March 2018, and therefore no longer available)."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12522-015-0211-y","article-title":"A multi-center, randomized, open-label, parallel group study of a natural micronized progesterone vaginal tablet as a luteal support agent in Japanese women undergoing assisted reproductive technology","volume":"14","author":"Fujiwara","year":"2015","journal-title":"Reprod. Med. Biol."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2020.06.021","article-title":"Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study","author":"Gerber","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0013","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.fertnstert.2012.07.1164","article-title":"Best practices of ASRM and ESHRE: a journey through reproductive medicine","volume":"98","author":"Gianaroli","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0014","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0015","article-title":"Randomized, assessor-blind, antim\u00fcllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization\/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta","author":"Ishihara","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/rmb2.12307","article-title":"Assisted reproductive technology in Japan: a summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology","volume":"19","author":"Ishihara","year":"2020","journal-title":"Reprod. Med. Biol."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0018","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/1471-0528.14241","article-title":"Effect of ethnicity on live birth rates after in vitro fertilisation\/intracytoplasmic sperm injection treatment: analysis of UK national database","volume":"124","author":"Maalouf","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0019","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/humrep\/dex094","article-title":"High FSH dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers","volume":"32","author":"Munch","year":"2017","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0020","first-page":"1","article-title":"Fertility problems: assessment and treatment","year":"2013","journal-title":"Natl. Inst. Heal. Care Excell. Guidel."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0021","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/humrep\/den480","article-title":"Anti-M\u00fcllerian hormone-based approach to controlled ovarian stimulation for assisted conception","volume":"24","author":"Nelson","year":"2009","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0022","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.fertnstert.2012.11.051","article-title":"Biomarkers of ovarian response: current and future applications","volume":"99","author":"Nelson","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0024","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/humrep\/dex319","article-title":"OPTIMIST study group. Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: the predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0026","unstructured":"Puregon. Summary of product characteristics. 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/puregon. Accessed 12 November 2020."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0027","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.fertnstert.2016.03.007","article-title":"Racial and ethnic disparities in assisted reproductive technology access and outcomes","volume":"105","author":"Quinn","year":"2016","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/humupd\/dmy033","article-title":"Fresh versus elective frozen embryo transfer in IVF\/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes","volume":"25","author":"Roque","year":"2019","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0029","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.fertnstert.2019.12.025","article-title":"Time to pregnancy: as important for patients as underestimated by doctors","volume":"113","author":"Roque","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.fertnstert.2020.04.027","article-title":"Total follicle stimulating hormone dose is negatively correlated with live births in a donor\/recipient model with fresh transfer: an analysis of 8,627 cycles from the Society for Assisted Reproductive Technology Registry","volume":"114","author":"Shaia","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0031","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0032","doi-asserted-by":"crossref","first-page":"m2519","DOI":"10.1136\/bmj.m2519","article-title":"Freeze-All versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial","volume":"370","author":"Stormlund","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.rbmo.2021.01.023_bib0033","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/humrep\/dex321","article-title":"OPTIMIST study group. Individualized FSH dosing based on ovarian reserve testing in women starting IVF\/ICSI: a multicentre trial and cost-effectiveness analysis","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2021.01.023_bib0034","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"OPTIMIST study group. Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: the predicted poor responder","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum. Reprod."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648321000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648321000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:19:52Z","timestamp":1761466792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648321000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1472648321000560"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2021.01.023","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2021.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.","name":"copyright","label":"Copyright"}]}}